News articles about argenx (NASDAQ:ARGX) have trended somewhat positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. argenx earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.0466562616514 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of analysts have recently commented on the company. Cowen reissued a “buy” rating on shares of argenx in a research note on Wednesday, June 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $130.00 price target on shares of argenx in a research note on Thursday, June 7th. ValuEngine raised argenx from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. JMP Securities lifted their price target on argenx from $93.00 to $130.00 and gave the company a “positive” rating in a research note on Monday, June 18th. Finally, Wedbush lifted their price target on argenx from $93.00 to $114.00 and gave the company an “outperform” rating in a research note on Monday, June 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $122.83.
Shares of ARGX opened at $89.74 on Friday. argenx has a 1 year low of $20.85 and a 1 year high of $103.00. The stock has a market cap of $2.89 billion, a PE ratio of -64.10 and a beta of 2.07.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: Stop Order
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.